thymic carcinoma (Cancer)
Information
- Disease name
- thymic carcinoma
- Disease ID
- DOID:3284
- Description
- "A thymus cancer that derives_from epithelial cells. The tumor cells in a thymic carcinoma look very different from the normal cells of the thymus, grow more quickly, and have usually spread to other parts of the body when the cancer is found." [url:http\://www.cancer.gov/cancertopics/pdq/treatment/thymoma/patient/page1]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| CDKN2A | 9 | 21,968,056 | 21,974,866 | 12 |
| TP53 | 17 | 7,668,421 | 7,687,490 | 10 |
| CDKN2B-AS1 | 9 | 21,994,778 | 22,039,498 | 8 |
| KIT | 4 | 54,657,913 | 54,740,770 | 4 |
| GNAQ | 9 | 77,716,097 | 78,031,811 | 2 |
| PIK3CA | 3 | 179,148,357 | 179,240,093 | 2 |
| TSC1 | 9 | 132,891,349 | 132,944,616 | 2 |
| AKT2 | 19 | 40,230,317 | 40,285,345 | 2 |
| SETD2 | 3 | 47,016,436 | 47,164,113 | 2 |
| RHOA | 3 | 49,359,145 | 49,411,976 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03134118 | Active, not recruiting | Phase 2 | Nivolumab in Patients With Type B3 Thymoma and Thymic Carcinoma (NIVOTHYM) | April 11, 2018 | July 2024 |
| NCT01025089 | Active, not recruiting | Phase 2 | Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma | December 2009 | December 2024 |
| NCT03921671 | Active, not recruiting | Phase 2 | Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT) | November 1, 2018 | July 16, 2024 |
| NCT03583086 | Active, not recruiting | Phase 1/Phase 2 | Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors | July 10, 2018 | July 2025 |
| NCT00314873 | Completed | Phase 1 | Pilot Study of Imatinib (Gleevec) as Treatment for Advanced Thymic Carcinoma | April 2006 | March 2011 |
| NCT00003662 | Completed | Phase 2 | Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases | August 1998 | January 2001 |
| NCT00965250 | Completed | Phase 2 | Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With Chemotherapy | August 2009 | June 2016 |
| NCT04430842 | Completed | Phase 1 | Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S | July 20, 2020 | December 22, 2022 |
| NCT03517488 | Completed | Phase 1 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors | July 10, 2018 | September 6, 2022 |
| NCT02307500 | Completed | Phase 2 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy | December 2014 | August 2020 |
| NCT02623127 | Completed | Phase 2 | A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma | October 2015 | October 2018 |
| NCT01364727 | Completed | Phase 2 | A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies | June 2011 | December 31, 2018 |
| NCT00589290 | Completed | Phase 2 | Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced Stage | December 2007 | June 2014 |
| NCT00010257 | Completed | Phase 2 | Carboplatin Combined With Paclitaxel in Treating Patients With Advanced Thymoma | June 19, 2001 | August 2012 |
| NCT00198133 | Completed | Phase 2 | Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma | January 2005 | May 2012 |
| NCT01385722 | Enrolling by invitation | Molecular Analysis of Thoracic Malignancies | August 2011 | June 2031 | |
| NCT06402708 | Recruiting | Phase 3 | Postoperative Adjuvant Chemotherapy for Thymic Cancer (FUSCC-Thymic 3) | April 9, 2024 | May 1, 2030 |
| NCT03076554 | Recruiting | Phase 2 | A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy | April 19, 2017 | June 30, 2025 |
| NCT03556228 | Recruiting | Phase 1 | Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | June 8, 2018 | June 2026 |
| NCT05667948 | Recruiting | Molecular Analysis and Treatment Options of Thymic Malignancies | January 1, 2016 | December 31, 2026 | |
| NCT06019468 | Recruiting | Phase 2 | Neoadjuvant Treatment For Locally Advanced Thymic Cancer | September 4, 2023 | December 30, 2025 |
| NCT06248515 | Recruiting | Phase 2 | A Phase II Trial of Sacituzumab Govitecan in Patients With Advanced Thymic Epithelial Tumors | April 25, 2024 | December 2026 |
| NCT06301945 | Recruiting | Artificial Intelligence Prediction Tool in Thymic Epithelial Tumors | August 1, 2023 | August 1, 2027 | |
| NCT03463460 | Suspended | Phase 2 | Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer | June 19, 2018 | December 31, 2025 |
| NCT01143545 | Terminated | Phase 1 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas | December 7, 2010 | February 26, 2020 |
| NCT01100944 | Terminated | Phase 1/Phase 2 | A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies | March 4, 2010 | October 21, 2015 |
| NCT01011439 | Terminated | Phase 2 | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | February 22, 2010 | December 17, 2018 |
| NCT04469725 | Terminated | Phase 2 | KN046 (a Humanized PD-L1/CTLA4 Bispecific Single Domain Fc Fusion Protein Antibody) in Subjects With Thymic Carcinoma | December 2, 2020 | July 7, 2023 |
| NCT04925947 | Terminated | Phase 2 | A Study of KN046 in Patients With Thymic Carcinoma Who Failed Immune Checkpoint Inhibitors | December 13, 2021 | May 5, 2023 |
| NCT02062632 | Terminated | Phase 2 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | April 14, 2014 | November 6, 2017 |
| NCT00818090 | Terminated | Phase 2 | Paclitaxel and Cisplatin for Thymic Neoplasm | September 2008 | November 2011 |
| NCT03449173 | Unknown status | Phase 2 | Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) | March 2, 2017 | May 31, 2022 |
| NCT02364076 | Unknown status | Phase 2 | Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma | March 2015 | December 2021 |
| NCT03170804 | Unknown status | Genomic Profiling of Nodular Thyroid Disease and Thyroid Cancer | January 1, 2017 | January 1, 2020 |
- Disase is a (Disease Ontology)
- DOID:3277
- Cross Reference ID (Disease Ontology)
- ICDO:8586/3
- Cross Reference ID (Disease Ontology)
- MESH:D013945
- Cross Reference ID (Disease Ontology)
- NCI:C7569
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:128717008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0205969
- Exact Synonym (Disease Ontology)
- malignant Thymoma
- Exact Synonym (Disease Ontology)
- Thymoma, malignant
- OrphaNumber from OrphaNet (Orphanet)
- 99868